

BioNTech Quietly Admits It Can't Prove 'Safety of COVID-19 Vaccine' in 2002 SEC Filing

Description

BioNTech, the German Big Pharma company that developed the Covid-19 vaccine in its Mainz biolab, has admitted it may not be able to demonstrate the efficacy of safety of its Covid-19 vaccine in order to gain permanent regulatory approval in the United States.

While we are eagerly waiting for the next Pfizer document dump, the BioNTech 2022 SEC filing makes for very interesting reading.

Just like in the 2021 Annual SEC Filing, Pfizer admits that due to **safety concerns** and **the inability to demonstrate sufficient efficacy**, they are not likely to receive regulatory approval.

Not that the Big Pharma vaccine cartel is concerned about this state of affairs. They know the Covid-19 vaccines will continue to be granted Emergency Use Authorization, regardless of whether they are effective and safe.

A notable change: " Undesirable Side Effects" in 2021 Filing has been upgraded to "Significant Adverse Events".

Will this damning **documented** admission be ignored again by the mainstream media and the majority of so-called alternative media the same way they ignored BioNTech's 2021 SEC filing?

Get ready for the never-ending state of emergency that will allow criminal world governments to mandate experimental gene therapy vaccines under the Emergency Use Authorization for years to come.



Excerpts:

Page 6

Risk Factors

Our revenue depends heavily on sales of our COVID-19 vaccine, and our future revenues from our COVID-19 vaccine are uncertain.

We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval.

Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates.

D. Risk Factors

Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any of following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not curren known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.

Investing in the ADSs involves various risks. You should carefully read and consider the matters discussed in this Annual Report under the heading "Risk Factors," which include following risks:

- Our revenue depends heavily on sales of our COVID-19 vaccine, and our future revenues from our COVID-19 vaccine are uncertain.
- Our reported commercial revenue is based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer Inc., or Pfizer, as Pfizer's fiscal quarter for subsidiaries outs the United States differs from ours and creates an additional time lag. These estimates are likely to change in future periods, which will impact our reported financial results.
- We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the Uni States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval.
- Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulat approval or market acceptance of any of our product candidates.
- We face significant competition from other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.
- We have only recently built our marketing and sales organization. If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.

by Baxter Dmitry

Category

1. Health-Wellness-Healing-Nutrition & Fitness
2. Main
3. Politics-Geopolitics-Gov.-Events
4. Science-Tech-AI-Medical & Gen. Research

Date Created
04/29/2022